Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ka-Yan Chiang"'
Autor:
Macy M. S. Lui, Yiu-Cheong Yeung, Jenny C. L. Ngai, Kit-Man Sin, Yi-Tat Lo, Alice P. S. Cheung, Ka-Yan Chiang, Yu-Hong Chan, Ken K. P. Chan, Connie H. K. Lam, Wei-Lam Law, Siu-Leung Fung, Wai-Kei Lam, David C. L. Lam, Lam-Hin Shek, Ida W. Y. Wong, Anthony P. Y. Yau, Yun-Chor Gary Lee, Johnny W. M. Chan
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Major advances in management of common pleural diseases have taken place in the past decade. However, pleural diseases are often managed by physicians of diverse training background and research on implementation of new knowledge
Externí odkaz:
https://doaj.org/article/37a7d815b77146c1bb35026f704f10ad
Publikováno v:
Respirology Case Reports, Vol 12, Iss 8, Pp n/a-n/a (2024)
Abstract Background Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with acute exacerbation (AECOPD) being a common sequalae which negatively impact health status, rates of hospitalization and readmission, and disease pro
Externí odkaz:
https://doaj.org/article/51e1c45c29f34472a20e72734417636c
Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong
Autor:
Wang Chun Kwok, Terence Chi Chun Tam, David Chi Leung Lam, Jackson Ka Chun Leung, King Pui Florence Chan, Shung Kay Samuel Chan, Ka Yan Chiang, Mary Sau Man Ip, James Chung Man Ho
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-8 (2023)
Abstract Background While there are postulations that asthma is potentially associated with severe coronavirus disease 2019 (COVID-19), there has been conflicting results from studies on the impact mild-to-moderate COVID-19 on asthma control after re
Externí odkaz:
https://doaj.org/article/e35ad755e8f3447e933e58d29672f9a4
Autor:
Ka Yan Chiang, Terence Chi Chun Tam, Wang Chun Kwok, James Chung-Man Ho, David C.L. Lam, Mary S.M. Ip
Publikováno v:
Clinical Cancer Drugs. 8:137-145
Background: As the commonest EGFR-TKI being used in Hong Kong, gefitinib has shown to be efficacious and safe as first-line treatment for L858R mutation and exon 19 deletions with less gastrointestinal and cutaneous adverse events than erlotinib and
Autor:
Terence Chi Chun Tam, James Chung-Man Ho, Ka Yan Chiang, Mary S.M. Ip, David C.L. Lam, Wang Chun Kwok
Publikováno v:
Journal of Chemotherapy. 32:429-436
Maintenance chemotherapy was studied in first line setting for advanced stage non-small cell lung carcinoma (NSCLC). There has not been any data on the role of continuation maintenance chemotherapy in second line setting. A retrospective cohort study
Autor:
Macy Mei Sze Lui, David C.L. Lam, Ka Yan Chiang, Mary S.M. Ip, Peony W C Chong, Terence Chi Chun Tam, James Chung-Man Ho, Yun Chor Gary Lee
Publikováno v:
Respirology. 25:1167-1173
BACKGROUND AND OBJECTIVE The advent of effective anti-cancer therapy has brought about uncertainty on the benefit of early definitive measures for newly diagnosed MPE from lung cancer. This study aims to investigate the outcomes of MPE in this settin
Autor:
James Chung-Man Ho, David C.L. Lam, Terence Chi Chun Tam, Wang Chun Kwok, Ka Yan Chiang, Mary S.M. Ip
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 162
Background Nephrotoxicity is one of the concerns of prolonged maintenance therapy with pemetrexed. No reversible risk factors for pemetrexed-induced nephrotoxicity have been identified in previous studies. Identification of such factors would be clin
Autor:
James Chung-Man Ho, Terence Chi Chun Tam, Wang Chun Kwok, David C.L. Lam, Tan Fong Cheong, Ka Yan Chiang, Mary S.M. Ip
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Background Pemetrexed was approved by United States Food and Drug Administration (US FDA) in combination with platinum for the treatment of advanced non-squamous non-small cell lung carcinoma (NSCLC) and malignant mesothelioma. Due to the structural
Publikováno v:
Current Pulmonology Reports. 7:13-18
The presence of driver mutations in lung cancer determines the natural course, options of specific targeted therapies and therefore prognosis and survival. The current review summarizes the knowledge about malignant pleural effusion (MPE) in lung can
Autor:
Ka-yan Chiang, Joycelyn Sim, Ming Yen Ng, Albert K. W. Lie, Chor Cheung Tam, Mei Sze Lui, Thomas S. Y. Chan, Mary Ip
Publikováno v:
Chest. 158:A395-A396